EntryPoint Capital’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
EntryPoint Capital's NPCE Position: Q2 2026 in Review
EntryPoint Capital increased its Neuropace (NPCE) stake by 38% in Q2 2026, buying an estimated $73.1K and bringing the position to 16,493 shares worth $262K. The position accounts for 0.06% of the portfolio, ranked #605.
EntryPoint Capital first reported a position in NPCE in Q1 2024 and has held it in 5 quarters since. The position peaked at $341K in Q1 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.
- EntryPoint Capital held 16,493 shares of Neuropace worth $262K as of Q2 2026.
- EntryPoint Capital bought 4,540 Neuropace shares in Q2 2026, an estimated $73.1K.
- Neuropace made up 0.06% of EntryPoint Capital's portfolio in Q2 2026, its #605 holding.
- EntryPoint Capital first reported a position in Neuropace in Q1 2024 and has held it in 5 quarters since.
- EntryPoint Capital's Neuropace position peaked at $341K in Q1 2025.
- 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.